Effect of Empagliflozin on Inflammation

NCT07292909 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

CAD - Coronary Artery Disease
Inflamation
PCI
SGLT 2 Inhibitors

Interventions

DRUG: Empagliflozin (SGLT2i)
DRUG: Placebo

Sponsor

Hotel Dieu de France Hospital